Comparative Evaluation of Quetiapine Plus Lamotrigine Versus Quetiapine Monotherapy in Bipolar Depression: A Randomized Placebo Controlled Trial (CEQUEL) by Geddes, J, Hinds, C, Rendell, J, Gardiner, A, Voysey, M, Attenburrow, M, Goodwin, G

Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. by Geddes, J, Gardiner, A, Rendell, J, Voysey, M, Tunbridge, E, Hinds, C, Yu, L, Hainsworth, J, Attenburrow, M, Simon, J, Goodwin, G, Harrison, P

“…The combination of lamotrigine plus quetiapine potentially offers improved outcomes for people with bipolar depression. …”

CEQUEL: A Comparative Evaluation of QUEtiapine-Lamotrigine combination versus quetiapine monotherapy, (and folic acid versus placebo) in people with bipolar depression: a 2x2 factorial randomised trial by Gardiner, A, Rendell, J, Stephens, W, Hainsworth, J, Yu, L, Brown, S, Goodwin, G, Geddes, J

Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. by Hayes, J, Marston, L, Walters, K, Geddes, J, King, M, Osborn, D

“…We aimed to compare rates of monotherapy treatment failure in individuals prescribed lithium, valproate, olanzapine or quetiapine by a population-based cohort study using electronic health records. 5,089 patients with bipolar disorder were prescribed lithium (N=1,505), valproate (N=1,173) olanzapine (N=1,366) or quetiapine (N=1,075) as monotherapy. …”

Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study by Hayes, J, Marston, L, Walters, K, Geddes, J, King, M, Osborn, D

“…We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment. …”

Self-harm, accidental injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study by Hayes, J, Pitman, A, Marston, L, Walters, K, Geddes, J, King, M, Osborn, D

“…After propensity score adjustment, accidental injury rates were lower in lithium compared to valproate (HR 1.32; 95%CI 1.10-1.58) and quetiapine (HR 1.34; 95%CI 1.07-1.69), but not olanzapine. …”

Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis by Cipriani, A, Barbui, C, Salanti, G, Rendell, J, Brown, R, Stockton, S, Purgato, M, Spineli, L, Goodwin, G, Geddes, J

“…Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. …”

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. by Cipriani, A, Barbui, C, Salanti, G, Rendell, J, Brown, R, Stockton, S, Purgato, M, Spineli, L, Goodwin, G, Geddes, J

“…Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. …”

Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial by Tunbridge, E, Attenburrow, M, Gardiner, A, Rendell, J, Hinds, C, Goodwin, G, Harrison, P, Geddes, J

“…<p><strong>Objectives</strong> CEQUEL (Comparative Evaluation of QUEtiapine plus Lamotrigine combination versus quetiapine monotherapy [and folic acid versus placebo] in bipolar depression) was a double‐blind, randomized, placebo‐controlled, parallel group, 2×2 factorial trial that examined the effect of adding lamotrigine and/or folic acid (FA) to quetiapine in bipolar depression. …”

A systematic review of the use of atypical antipsychotics in autism. by Barnard, L, Young, A, Pearson, J, Geddes, J, O'Brien, G

“…Olanzapine and clozapine may also be effective; however, there is little evidence for using amisulpride or quetiapine in this population. Randomized trials are required to clarify the effectiveness of these agents.…”

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder by Cipriani, A, Barbui, C, Rendell, J, Geddes, J

“…Results: Six placebo-controlled trials comparing aripiprazole, olanzapine, quetiapine and ziprasidone were found in the FDA website. …”

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. by Cipriani, A, Barbui, C, Rendell, J, Geddes, J

“…RESULTS: Six placebo-controlled trials comparing aripiprazole, olanzapine, quetiapine and ziprasidone were found in the FDA website. …”

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. by Geddes, J, Freemantle, N, Harrison, P, Bebbington, P

“…SUBJECTS: 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. …”

Treatment of bipolar disorder. by Geddes, J, Miklowitz, D

“…Antipsychotic drugs are effective in the acute treatment of mania; their efficacy in the treatment of depression is variable with the clearest evidence for quetiapine. Despite their widespread use, considerable uncertainty and controversy remains about the use of antidepressant drugs in the management of depressive episodes. …”

Bipolar disorder. by Geddes, J, Briess, D

“…CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antidepressants, carbamazepine, chlorpromazine, clonazepam, cognitive therapy, education, family-focused psychoeducation, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, psychological treatments, quetiapine, risperidone, topiramate, valproate, and ziprasidone.…”

Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies by Kessing, L, Bauer, M, Nolen, W, Severus, E, Goodwin, G, Geddes, J

“…<strong>Results:</strong> In eight out of nine identified studies including more than a total of 14.000 patients, maintenance lithium monotherapy was associated with improved outcome compared with another mood stabilizer in monotherapy including valproate, lamotrigine, olanzapine, quetiapine, unspecified anticonvulsants, carbamazepine/lamotrigine, unspecified atypical antipsychotics and unspecified antipsychotics. …”

Lithium for acute mania by McKnight, R, De La Motte De Broöns De Vauvert, S, Chesney, E, Amit, B, Geddes, J, Cipriani, A

“…Limited evidence suggests little or no difference between lithium and other mood stabilisers (valproate, carbamazepine) or antipsychotics (risperidone, quetiapine, haloperidol). Olanzapine may be an exception, as it is probably slightly more effective than lithium. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis by Leucht, S, Örey, D, Richter, F, Samara, M, Kissling, W, Stapf, M, Lässig, B, Cipriani, A, Barbui, C, Spineli, L, Mavridis, D, Salanti, G, Engel, R, Geddes, J, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0.88, 0.73-1.03; amisulpride 0.66, 0.53-0.78; olanzapine 0.59, 0.53-0.65; risperidone 0.56, 0.50-0.63; paliperidone 0.50, 0.39-0.60; zotepine 0.49, 0.31-0.66; haloperidol 0.45, 0.39-0.51; quetiapine 0.44, 0.35-0.52; aripiprazole 0.43, 0.34-0.52; sertindole 0.39, 0.26-0.52; ziprasidone 0.39, 0.30-0.49; chlorpromazine 0.38, 0.23-0.54; asenapine 0.38, 0.25-0.51; lurasidone 0.33, 0.21-0.45; and iloperidone 0.33, 0.22-0.43. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. by Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, R, Geddes, J, Kissling, W, Stapf, M, Lässig, B, Salanti, G, Davis, J

“…The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. …”